Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

11 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 36 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry; Liver Assessment; Laboratory - Thyroid Function Test; Urinalysis; Urinalysis - Local: 24h Protein Details; Target Lesion Assessments; Confirmatory Response; Investigational Product Compliance - Pazopanib, 12-Lead ECG

- 22/05/2019 - 1 Formulaire, 13 Groupes Item, 188 Eléments de données, 1 Langue
Groupes Item: Date of visit/ assessment, Vital Signs, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Liver Assessment, Local Laboratory - Thyroid Function, Local Laboratory - Urinalysis, Urinalysis - Local: 24 hour Protein Details, Target Lesion Summary, Confirmatory Response - Response Summary, Confirmatory Response - New Lesions, Investigatoinal Product Compliance - Pazopanib, 12-Lead ECG
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 30 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry; Liver Assessment; Local Laboratory - Thyroid Function Test; Urinalysis; Urinalysis - Local: 24h Protein Details; Investigational Product Compliance - Pazopanib; Target Lesion Assessments; Confirmatory Response

- 22/05/2019 - 1 Formulaire, 12 Groupes Item, 182 Eléments de données, 1 Langue
Groupes Item: Date of visit/ assessment, Vital Signs, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Liver Assessment, Local Laboratory - Thyroid Function , Local Laboratory - Urinalysis, Urinalysis - Local: 24 hour Protein Details, Investigatoinal Product Compliance - Pazopanib, Target Lesion Summary, Confirmatory Response - Response Summary, Confirmatory Response - New Lesions
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 24 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry; Liver Assessment; Laboratory - Thyroid Function Test; Urinalysis; Urinalysis - Local: 24h Protein Details; Investigational Product Compliance - Pazopanib; Target Lesion Assessments; Confirmatory Response

- 22/05/2019 - 1 Formulaire, 13 Groupes Item, 188 Eléments de données, 1 Langue
Groupes Item: Date of visit/ assessment, Vital Signs, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Liver Assessment, Local Laboratory - Thyroid Function, Local Laboratory - Urinalysis, Urinalysis - Local: 24 hour Protein Details, Target Lesion Summary, Confirmatory Response - Response Summary, Confirmatory Response - New Lesions, Investigatoinal Product Compliance - Pazopanib, 12-Lead ECG
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 18 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry; Liver Assessment; Local Laboratory - Thyroid Function Test; Urinalysis; Urinalysis - Local: 24h Protein Details; Investigational Product Compliance - Pazopanib; Target Lesion Assessments; Confirmatory Response

- 21/05/2019 - 1 Formulaire, 12 Groupes Item, 182 Eléments de données, 1 Langue
Groupes Item: Date of visit/ assessment, Vital Signs, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Liver Assessment, Local Laboratory - Thyroid Function , Local Laboratory - Urinalysis, Urinalysis - Local: 24 hour Protein Details, Investigatoinal Product Compliance - Pazopanib, Target Lesion Summary, Confirmatory Response - Response Summary, Confirmatory Response - New Lesions
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 6 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry; Liver Assessment; Urinalysis; Urinalysis - Local: 24h Protein Details; Investigational Product Compliance - Pazopanib; Target Lesion Assessments; Confirmatory Response

- 21/05/2019 - 1 Formulaire, 11 Groupes Item, 166 Eléments de données, 1 Langue
Groupes Item: Date of visit/ assessment, Vital Signs, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Liver Assessment, Local Laboratory - Urinalysis, Urinalysis - Local: 24 hour Protein Details, Investigatoinal Product Compliance - Pazopanib, Target Lesion Summary, Confirmatory Response - Response Summary, Confirmatory Response - New Lesions
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 12 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry; Liver Assessment; Laboratory - Thyroid Function Test; Urinalysis; Urinalysis - Local: 24h Protein Details; Target Lesion Assessments; Confirmatory Response; Investigational Product Compliance - Pazopanib, 12-Lead ECG

- 21/05/2019 - 1 Formulaire, 13 Groupes Item, 188 Eléments de données, 1 Langue
Groupes Item: Date of visit/ assessment, Vital Signs, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Liver Assessment, Local Laboratory - Thyroid Function, Local Laboratory - Urinalysis, Urinalysis - Local: 24 hour Protein Details, Target Lesion Summary, Confirmatory Response - Response Summary, Confirmatory Response - New Lesions, Investigatoinal Product Compliance - Pazopanib, 12-Lead ECG
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 8 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry, Liver Events Assessment; Urinalysis; Urinalysis - Local: 24h Protein Details; Investigational Product Compliance - Pazopanib; Biomarker Samples

- 17/05/2019 - 1 Formulaire, 9 Groupes Item, 158 Eléments de données, 1 Langue
Groupes Item: Date of visit/ assessment, Vital Signs, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Local Laboratory - Urinalysis, Urinalysis - Local: 24 hour Protein Details, Liver Assessment, Investigatoinal Product Compliance - Pazopanib , Biomarker Sample
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 4 - Vital Signs; 12-Lead- ECG; Local Laboratory - Haematology, Clinical Chemistry, Liver Assessment; Urinalysis; Urinalysis - Local: 24h Protein Details; Investigational Product Compliance - Pazopanib; Biomarker Samples

- 17/05/2019 - 1 Formulaire, 10 Groupes Item, 164 Eléments de données, 1 Langue
Groupes Item: Date of visit/ assessment, Vital Signs, 12-Lead ECG, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Local Laboratory - Urinalysis, Urinalysis - Local: 24 hour Protein Details, Liver Assessment, Investigatoinal Product Compliance - Pazopanib , Biomarker Sample
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 2 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry; Liver Assessment; Urinalysis; Urinalysis - Local: 24h Protein Details; Investigational Product Compliance - Pazopanib

- 17/05/2019 - 1 Formulaire, 8 Groupes Item, 152 Eléments de données, 1 Langue
Groupes Item: Date of visit/ assessment, Vital Signs, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Liver Assessment, Local Laboratory - Urinalysis, Urinalysis - Local: 24 hour Protein Details, Investigatoinal Product Compliance - Pazopanib
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 1 - Vital Signs; 12-Lead- ECG; Local Laboratory - Haematology, Clinical Chemistry; Investigational Product Compliance - Pazopanib; Liver Events Assessment; Biomarker Samples

- 16/05/2019 - 1 Formulaire, 8 Groupes Item, 149 Eléments de données, 1 Langue
Groupes Item: Date of visit/ assessment, Vital Signs, 12-Lead ECG, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Investigational Product Compliance - Pazopanib, Liver Events Assessment, Biomarker Sample
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Screening - Vital Signs; 12-Lead- ECG; Local Laboratory - Haematology, Clinical Chemistry, Coagulation, Thyroid Function Test, Urinalysis; Urinalysis - Local: 24h Protein Details; Measurable/ Non-measurable Disease (Lesions)

- 16/05/2019 - 1 Formulaire, 10 Groupes Item, 187 Eléments de données, 1 Langue
Groupes Item: Date of visit/ assessment, Vital Signs, 12-Lead ECG, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Local Laboratory - Coagulation, Local Laboratory - Thyroid Function, Local Laboratory - Urinalysis, Urinalysis - Local: 24 hour Protein Details, Measurable/ Non-measurable Disease (Lesions)
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial